Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2705454 | 1.00 | KDM4E (0.38) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL7306465 | 1.00 | KDM4E (0.38) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL132277 | 1.00 | KDM4E (0.38) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL7307615 | 1.00 | KDM4E (0.38) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL7312757 | 1.00 | KDM4E (0.38) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL2389792 | 0.98 | DPP4 (0.37) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL9684605 | 0.98 | DPP4 (0.37) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL3316703 | 0.98 | DPP4 (0.37) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL1567974 | 0.98 | DPP4 (0.37) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL4892915 | 0.98 | DPP4 (0.37) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078954-B2 | Multifunctional filler granule | Pobi Concept Oy (FI) | 2015-07-14 | — | — | US | disclosed |
| EP-2634207-B1 | A multifunctional filler granule | Pobi Concept Oy (FI) | 2014-04-30 | — | — | EP | disclosed |
| US-20130230563-A1 | Multifunctional Filler Granule | Pobi Concept Oy (FI) | 2013-09-05 | — | — | US | disclosed |
| EP-2634207-A1 | A multifunctional filler granule | Pobi Concept Oy (FI) | 2013-09-04 | — | — | EP | disclosed |
| EP-2240521-A1 | POLYMER ORGANOCATALYST AND PREPARATION PROCESS | Universitetet I Oslo (NO) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009087177-A1 | POLYMER ORGANOCATALYST AND PREPARATION PROCESS | UNIVERSITETET I OSLO (NO) | 2009-07-16 | — | — | WO | disclosed |
| US-20090118353-A1 | Medicinal composition | KITAJIMA AKIHIKO | 2009-05-07 | — | — | US | disclosed |
| US-7485665-B2 | Medicinal composition | NAGASE CHEMTEX CORPORATION (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-20050239861-A1 | Medicinal composition | NAGASE CHEMTEX CORPORATION (JP) | 2005-10-27 | — | — | US | disclosed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| EP-0481756-B1 | Benzamide derivatives | TEIKOKU CHEM IND CO LTD (JP) | 1997-07-09 | — | — | EP | disclosed |
| US-5405847-A | Antiallergic, antiasthmatic, anxiolytic, hypotensive agents | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1995-04-11 | — | — | US | disclosed |
| CN-1088928-A | New 4,5-dihydro-4-oxo-pyrrolo-[1,2-α] quinazolinone | ASTA MEDICA AG (DE) | 1994-07-06 | — | — | CN | disclosed |
| US-5143935-A | Gastrointestinal disorders | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| EP-0481756-A2 | Benzamide derivatives | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
| US-4684658-A | Anti-thrombotic ortho-condensed pyrrole derivatives, compositions, and method of use therefor | RHONE-POULENC SANTE (FR) | 1987-08-04 | — | — | US | disclosed |
| US-4555508-A | Antihypertensive spiro-cyclic compounds | USV PHARMACEUTICAL CORP. (US) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239861-A1 | Medicinal composition | HTR4, HTR2C, HTR1A | DPP4 573/4885KDM4E 2006/4885CYP1A2 621/4885 |
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | DPP4 231/4885KDM4E 4713/4885CYP1A2 4278/4885 |
| US-20090118353-A1 | Medicinal composition | HTR4, FABP2, SLC10A2 | DPP4 491/4885KDM4E 2503/4885CYP1A2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.